Key facts
- This page summarizes Stephen J. Sullivan's Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Aug 2026, 17:00.
Stephen J. Sullivan - 20 Aug 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)
- Reporting relationship
- Director
- Issuer ticker
- IDXG
- Reported as of
- 20 Aug 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ STEPHEN J SULLIVAN
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Stephen J. Sullivan filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 20 Aug 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001229881
Primary reporting owner
SULLIVAN STEPHEN J
- Relationship
- Director
- Address
- C/O INTERPACE BIOSCIENCES, INC., 2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310, PARSIPPANY
- Signature
- /s/ STEPHEN J SULLIVAN
- Signature date
- 20 Aug 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IDXG
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- Shares
- +69,252
- Change %
- Price
- $0.000000*
- Shares after
- 69,252
- Date
- 20 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 69,252
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.
Footnote F2
The restricted stock units vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.